Company / Return on Equity (ROE)
Dyne Therapeutics, Inc. Return on Equity (ROE) History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-50.4%
FY2024
5-year range
-258.4% / -17.4%
FY2020-FY2024
Trend
+80.5%
vs FY2023
Sector context
#135 of 190
Health Care
What the data says
Dyne Therapeutics, Inc. reports negative total equity of -50.4% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-50.4% in FY2024 with a 5-year CAGR of +55.5%.
Improved from -66.6% to -50.4% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -9.8pp
- 5-Year Change
- +55.5pp
- 10-Year Change
- -
Sector benchmark
In line with sector averageTop 71% of 190This company -50.4% Sector average -50.3%
▼
In line with sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 80.5% year-over-year.
- Currently 0.1pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2020.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -50.4% | +80.5% |
| FY2023 | -258.4% | -288.0% |
| FY2022 | -66.6% | -64.3% |
| FY2021 | -40.6% | -133.6% |
| FY2020 | -17.4% | +83.6% |
| FY2019 | -105.9% | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026